The double‐blind, placebo‐controlled study was conducted between March 2016 and July 2017 with 25 patients of a mean age of 48 at the Pain Research Unit of the Rambam Health Care Campus in Haifa in partnership with Israeli medical device firm Syqe Medical, the developer of the world’s first selective-dose, pharmaceutical-grade medicinal plants inhalers.
Read more here.
